6 assets in Bladder Adenocarcinoma

Therapeutic assets addressing Bladder Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Bladder Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cabozantinib Bladder Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Bladder Adenocarcinoma	Emory University	P2	CCC (53)
Ipilimumab Bladder Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Bladder Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pembrolizumab Bladder Adenocarcinoma	Emory University	P2	CCC (53)